A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej i możliwość wyrażenia świadomej zgody
- •Identyfikowalny nowotwór mierzalny za pomocą standardowych badań
- •Rak płuc małokomórkowy, duże-komórkowy lub nowotwór neuroendokrynny poza płucami, zaawansowany i nieresekcyjny
- •Nowotwory mieszanego typu kwalifikują się, jeśli komponent neuroendokrynny stanowi co najmniej 50% tkanki
- •Pacjenci mogą mieć wcześniej przebytą chemioterapię lub inne leczenie
- •Nowotwory z pozytywnym markerem DLL3
✗ Disqualifies
- •Raki neuroendokrynne powstałe w wyniku transformacji z innego typu raka płuca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (15)
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
Sarah Cannon Research Institute at HealthONE
Denver, United States
Yale University Cancer Center
New Haven, United States
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Washington University School of Medicine (Siteman Cancer Center)
St Louis, United States
University of North Carolina at Chapel Hill
Chapel Hill, United States
Duke University Medical Center
Durham, United States
Sarah Cannon Research Institute University of Oklahoma
Oklahoma City, United States
Providence Portland Medical Center
Portland, United States
Mays Cancer Center / University of Texas, San Antonio
San Antonio, United States
NEXT Virginia
Fairfax, United States
Fred Hutch Cancer Center
Seattle, United States
Trial contact
Phanes Therapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.